#$LLY is an active hashtag on Bluesky. In the last 30 days, 29 people shared 64 posts with it — around 2 a day. Activity is up 517% versus the previous week, peaking on Aug 5 with 21 posts.

Posts with #$LLY

Carl Quintanilla

@carlquintanilla.bsky.social

about 2 months ago

“.. given the patient demographics and the unusual nature of the application, STAT asked the White House whether the patient was President Trump ..” $LLY

Lizzy Lawrence @lizzylawrence.bsky.social

EXCLUSIVE: Eli Lilly gave compassionate use access to retatrutide, their unapproved powerful obesity drug, to a 79-year-old man in April. The application was arranged by a top doctor at NIH, and cleared by the FDA. www.statnews.com/2026/06/23/e...

www.statnews.com

19 87 256

George Pearkes

@peark.es

2 months ago

$LLY rolling GLP-1 profits into vaccines, which is a welcome sign.

www.wsj.com

Exclusive | Lilly Agrees to Buys Trio of Vaccine Developers

The weight-loss drug market leader is renewing a focus on infectious-disease prevention.

3 18 182

Quantian

@quantian.bsky.social

3 months ago

Napkin math on $LLY retatrutide P3 top line readout implies (full results forthcoming) the drug has a 99.5% efficacy rate and a 2.75σ effect size vs placebo. Not quite perfect separation between control and experimental arm like in the P2, but among the most successful drug trials in history.

7 18 140

Carl Quintanilla

@carlquintanilla.bsky.social

29 days ago

(via Angelica Peebles) $LLY $NVO

6 14 102

Carl Quintanilla

@carlquintanilla.bsky.social

3 months ago

$LLY

FinTwitter @fintwitter.bsky.social

LILLY SAYS WE NOW HAVE JUST OVER 20000 PATIENTS TREATED TO DATE WITH FOUNDAYO: CONF CALL

0 6 67

Nancy Levine Stearns

@nancylevinestearns.bsky.social

about 2 months ago

Lilly CEO Dave Ricks announced that Lilly is a proud participant in Trump’s Freedom 250, the White House-backed hijack of America’s birthday. What is Lilly’s message about Trump’s war on science? #Science $LLY

8 22 56

Lou Mannheim

@loumannheim87.bsky.social

7 days ago

$LLY $NVO ... Barrons with a cover story on GLP1 drugs. Race to see who makes a bigger contribution to humanity-- GLP1 or AI

2 0 10

midgardfinance.com

@midgardfinance.com

2 days ago

🇩🇰 $NOVO ran CagriSema head to head against 🇺🇸 $LLY Tirzepatide, and reported it in one line. #REIMAGINE4, 68 weeks: weight loss 15.2% vs 15.8%, HbA1c 1.9 vs 2.2 points. Non-inferiority met on weight, not met on glucose. midgardfinance.com/compan… #pharma $NVO #CagriSema #Tirzepatide

Two bar charts side by side on a dark background, titled "REIMAGINE 4: CagriSema against tirzepatide". Each panel compares two bars: CagriSema, made by Novo Nordisk, in blue, and tirzepatide, made by Eli Lilly, in red. Each company's name is printed under its bar.

The left panel is weight loss at 68 weeks. CagriSema 15.2 percent, tirzepatide 15.8 percent. The panel is labelled "non-inferiority met".

The right panel is HbA1c reduction at 68 weeks, measured in percentage points. CagriSema 1.9, tirzepatide 2.2. The panel is labelled "non-inferiority NOT met".

The two bars are close in both panels, but the trial's dual primary endpoints were judged separately. CagriSema met the non-inferiority margin against tirzepatide on weight reduction and did not meet it on blood glucose. Failing to demonstrate non-inferiority is not the same as being shown inferior; the trial did not establish that tirzepatide is better on HbA1c, only that CagriSema did not prove itself no worse.

The trial was open-label, ran 68 weeks, and enrolled about 1,000 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Figures are on the basis of the effect if all participants adhered to treatment.

0 0 3

midgardfinance.com

@midgardfinance.com

2 days ago

Both raised 2026 guidance within a day of each other. Both called it a raise. 🇩🇰 $NOVO now guides to 0% to -6%. 🇺🇸 $LLY now guides to +30% to +33%. One of them is raising its way to a smaller year. midgardfinance.com/compan… #pharma $NVO

Bar chart on a dark background titled "2026 guidance, after both companies raised it". The vertical axis is full-year 2026 revenue growth guidance, running from minus 20 percent to plus 40 percent, with a bright line at zero.

Five floating range bars in two groups, each bar spanning the low and high end of a guidance range, shaded palest for the oldest vintage.

Novo Nordisk, in light blue, sits entirely below or at the zero line. Guidance of 3 February ran from minus 13 to minus 5 percent. Guidance of 6 May ran from minus 12 to minus 4. The current guidance, issued 4 August, runs from minus 6 to zero.

Eli Lilly, in violet, sits far above. Its prior guidance converts to roughly plus 26 to plus 30 percent, and its updated guidance to plus 30 to plus 33 percent.

Both companies moved their ranges upward, and both described it as a raise. The two sets of bars do not come close to overlapping: the top of Novo's range is about thirty points below the bottom of Lilly's.

The two figures are not measured the same way, and the chart says so underneath. Novo's is adjusted sales growth at constant exchange rates, excluding a one-off rebate reversal. Lilly's is reported revenue growth in dollars, converted from its dollar guidance of 85 to 87 billion against 2025 revenue of 65.2 billion.

1 1 3

George Pearkes

@peark.es

6 months ago

$LLY also guiding material price declines but guidance handily topped estimates. Orforglipron is their oral GLP-1. *ELI LILLY SEES 2026 REV. $80B TO $83B, EST. $77.71B *ELI LILLY SEES GLOBAL PRICING DECLINE IN LOW- TO MID-TEENS *LILLY EXPECTS ORFORGLIPRON U.S. LAUNCH IN 2Q, PENDING FDA NOD

George Pearkes @peark.es

OOF $NVO

2025 YEAR RESULTS
• Sales DKK309.06 billion, estimate DKK307.62
billion (Bloomberg Consensus)
• Ebit DKK127.66 billion, estimate DKK129.56 billion
• Net income DKK102.43 billion, estimate
DKK103.31 billion
• EPS DKK23.03, estimate DKK23.28
YEAR FORECAST
• Sees sales at constant exchange rates - 5% to
-13%, estimate -1.39%
• Sees operating profit at constant FX -5% to - 13%, estimate - 3.12%

3 3 21

Nancy Levine Stearns

@nancylevinestearns.bsky.social

about 2 months ago

Union of Concerned Scientists: "Last week, the White House released draft regulations that—if enacted—will upend US science as we know it." How does Lilly reconcile is proud participation in Trump's Freedom 250 with Trump's war on science? #Science $LLY blog.ucs.org/alexa-dietri...

blog.ucs.org

The Trump Administration Has Launched Its Biggest Threat Yet to Scientific Research. We Can Stop Them.

This proposed rule is about one thing: the Trump administration’s hunger to exert control over the federal scientific enterprise and re-direct it toward their own political agenda. It's an attack on s...

2 8 21

Robert Lee

@roberee.bsky.social

2 days ago

$LLY $NVO both are buys but for different reasons/investors

1 0 1

@fundfollower.bsky.social

about 4 hours ago

🆕 Alphinity Investment Management opened a brand-new position in $LLY — 6.0% of the portfolio straight out of the gate.

1 0 0

Biotech Hangout

@biotechhangout.bsky.social

1 day ago

#BiotechHangout: Sam Fazeli, Brian Skorney, Yaron Werber, Jake Becraft on deals: $AZN/$BMY M&A talk, reverse mergers, IPOs, policy: China, $MIRM, $REPL's Tudriqev approval, company news: $BNTX vs $MRNA, $LLY vs $NVO, $ASND/$BMRN in achondroplasia, data: Otsuka's Voyxact: bit.ly/4fF5Io8

0 0 0

Allen3D

@hex720.net

2 days ago

Wonder if I should cutback my position on $LLY

0 0 0

robot2trade

@robot2trade.bsky.social

2 days ago

Market Heatmap – Aug 6 Leaders: $MSFT +2.6% | $UBER +3.4% | $LLY +1.9% | $DIS +2.9% | $XOM +2.1% Laggards: $WDC -13% | $DELL -5.5% | $CRM -3.2% | $BA -3.3% | $SNDK -6.8% Mixed tech, energy firm. #Stocks

0 0 0

Robert Lee

@roberee.bsky.social

2 days ago

$LLY $NVO both are buys but for different reasons/investors

1 0 1

midgardfinance.com

@midgardfinance.com

2 days ago

0 0 3

midgardfinance.com

@midgardfinance.com

2 days ago

1 1 3

robot2trade

@robot2trade.bsky.social

3 days ago

Market Heatmap Snapshot Green: $NVDA +3.9% • $ANET +4.5% • $LLY +4.8% • $DIS +3.5% Red: $AMD -6.6% • $GOOGL -4.1% • $AMZN -2.1% • $TSLA -1.6% Mixed session. #Stocks #Market

0 1 1

FirstWord Group

@firstwordgroup.com

3 days ago

Lilly sees Foundayo 'inflection' after softer-than-expected sales $LLY firstwordpharma.com/story…

0 0 0

Biostock

@biostock.bsky.social

3 days ago

🟢 $LLY — Regulatory Designation FDA Breakthrough Therapy Designation - Olomorasib in KRAS G12C-Mutant Pancreatic Cancer FDA granted Breakthrough Therapy designation to olomorasib for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cance… biostock.app/symbols/LLY

0 0 0

Biostock

@biostock.bsky.social

3 days ago

🟢 $LLY — Regulatory Approval FDA Approval - EBGLYSS (Lebrikizumab) Every-Eight-Week Maintenance Dosing FDA approved EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis. biostock.app/symbols/LLY

0 0 0

Biostock

@biostock.bsky.social

3 days ago

🟢 $LLY — Regulatory Approval European Commission Approval - Jaypirca (Pirtobrutinib) Monotherapy Across All Lines of CLL European Commission approved Jaypirca (pirtobrutinib) as monotherapy for adults with chronic lymphocytic leukemia (CLL) across all lines of … biostock.app/symbols/LLY

0 0 0

Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.

📊 User Rankings

📈 Bluesky Growth Stats

📰 Content Rankings

📚 Feed Tools & Insights

🛠️ Additional Tools & Resources

❓ Frequently Asked Questions

#$LLY

#$LLY posts per day (last 30 days)

Related tags

Posts with #$LLY

Explore trending tags